Minjie Wei

机构：Shenyang Medical College, China Medical University · ORCID：0009-0007-5414-6784

发表论文 28 篇 · 总被引 812 次 · h-index 8

代表论文

• Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals (2025 · Journal of Hematology & Oncology · 被引 234)
• Cell-specific mechanisms of TMEM16A Ca2+-activated chloride channel in cancer (2017 · Molecular Cancer · 被引 148)
• Clinical significance of FBXW7 loss of function in human cancers (2022 · Molecular Cancer · 被引 144)
• The Analysis of Key Factors Related to ADCs Structural Design (2019 · Frontiers in Pharmacology · 被引 69)
• HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy (2016 · Japanese Journal of Clinical Oncology · 被引 50)
• Advances in cancer treatment: a new therapeutic target, Annexin A2 (2021 · Journal of Cancer · 被引 45)